Compare Immunovant Inc. Common Stock (IMVT) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Marsh & McLennan Companies, Inc. — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while Marsh & McLennan Companies, Inc. trades at $176.51 (market cap $82.87B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 12.5× Immunovant Inc. Common Stock's market cap, and Marsh & McLennan Companies, Inc. pays a 2.28% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Marsh & McLennan Companies, Inc. for 109 Days on average.
| IMVT | MRSH | |
|---|---|---|
Market Cap | $6.62B | $82.87B |
Volume | 1,131,364 | 2,731,994 |
Sector | Health | Financials |
52-Week High | $44.96 | $207.02 |
52-Week Low | $17.03 | $157.32 |
Typical Hold Time | 0 Days | 109 Days |
Enterprise Value | $5.72B | $103.55B |
Dividend Yield | — | 2.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Marsh (MRSH) trades at $176.67, up 2.86% today, with a bullish technical signal and strong fundamentals including a 14.24% net income margin and consistent earnings beats. The recent acquisition of Accel Holdings, completed October 2, 2026, enhances its global advisory services. Revenue grew to $26.98B in 2025, and cash flow from operations remains robust at $5.29B, supporting a stable financial position.
The stock offers upside to the consensus price target of $202.71, but risks include high debt levels and competitive pressures. Analyst sentiment is mixed with a 'Hold' consensus, while technical indicators show overbought conditions near resistance at $177. Long-term growth depends on integration of acquisitions and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
